Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International, Inc. (NASDAQ: DYAI) announced its participation in three industry events in June 2022, aimed at advancing its proprietary C1 protein production platform. The events are:

• Vaccine Technology VIII: June 12-17, 2022, Sitges, Spain
• BIO International Convention: June 13-16, 2022, San Diego, CA
• Future Food-Tech Alternative Proteins: June 21-22, 2022, New York, NY

Management will be available for one-on-one meetings. The C1 platform is focused on reducing costs and enhancing the efficacy of biologic vaccines and drugs.

Dyadic International (NASDAQ: DYAI) announced that CEO Mark Emalfarb will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 3:00 PM ET. The presentation will showcase Dyadic's proprietary C1-cell protein production platform aimed at enhancing biologic vaccines and drugs. A live webcast will be available for viewing, and a replay will be archived on the company's website. Investors can also arrange one-on-one meetings with the CEO for more detailed discussions.

Dyadic International (NASDAQ: DYAI) announced its participation in the 2022 H.C. Wainwright Global Investment Conference held from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. President and CEO, Mark Emalfarb, will present on May 25, 2022, at 12:30 PM ET. The management team will also host one-on-one meetings, accessible through a request at hzosiak@dyadic.com. Dyadic focuses on developing its proprietary C1-cell protein production platform to enhance the efficiency and cost-effectiveness of biologic vaccines and drugs.

Dyadic International (NASDAQ: DYAI) reported a 40.8% revenue increase in Q1 2022, reaching approximately $534,000. The company secured a new collaboration with a global food ingredients firm and a license deal with Phibro for animal vaccines. Positive developments include advancing a first-in-human clinical trial application for the DYAI-100 COVID-19 vaccine in South Africa, while a C1-produced antibody showed efficacy against Omicron variants. Cash and investments stood at $17.5 million as of March 31, 2022, against a net loss of approximately $2.49 million.

Dyadic International, Inc. (NASDAQ: DYAI) has entered into a Joint Development Agreement with a Global Food Ingredients Company to produce animal-free ingredient products. The project is fully funded with €3.6 million. Dyadic will develop proprietary production cell lines and can earn success and commercialization fees, along with royalties on sales. This partnership illustrates Dyadic's capacity to leverage its C1 protein production platform beyond biopharmaceuticals, tapping into emerging markets and enhancing its value in biomanufacturing.

Dyadic International announced positive results from a toxicology study of its COVID-19 vaccine candidate, DYAI-100, published in Toxicologic Pathology. The study revealed an excellent safety profile and strong immunogenic responses in animal models. The findings support Dyadic’s upcoming First-In-Human clinical trial and validate its C1-cell protein production platform, which aims to lower biopharmaceutical production costs. This marks Dyadic's third peer-reviewed publication in 2022 regarding the efficacy and safety of its products.

Dyadic International, Inc. (NASDAQ: DYAI) announced its upcoming financial results report for Q1 2022, scheduled for May 12, 2022, at 5:00 p.m. ET. The company specializes in using its proprietary C1-cell protein production platform to enhance the development and production of biologic drugs and vaccines at lower costs. The conference call will discuss financial performance and future strategies, accessible via specific dial-in numbers or a webcast link. Dyadic aims to leverage its C1 technology to improve access to biologics and save lives.

Dyadic International, Inc. (NASDAQ: DYAI) announced that its licensee, Epygen Biotech, received funding from India's Department of Biotechnology to support Phase 1 and 2 clinical trials of a COVID-19 vaccine using Dyadic's C1 protein production platform. Epygen aims to develop a low-cost vaccine, anticipated to be priced around $2 per dose, targeting the production of 100 million doses annually. Additionally, Epygen plans to raise $26 million for Phase 3 trials to enhance production capacity and expedite vaccine availability.

Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced its participation in key scientific meetings in April 2022. The company will present its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development during the Microbial Engineering II conference in Portugal and the World Vaccine Congress in Washington, DC. Presentations will cover topics including therapeutic protein production and innovative vaccine manufacturing solutions, showcasing how C1 can reduce costs and improve efficiency in biopharmaceuticals.